Sino Biopharmaceutical Limited (SBHMY)
USD 8.34
(0.0%)
USD 8.34
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 15.53 Billion CNY | -6.09% |
| 2022 | 16.94 Billion CNY | -1.38% |
| 2021 | 17.18 Billion CNY | 21.36% |
| 2020 | 14.16 Billion CNY | -0.39% |
| 2019 | 14.21 Billion CNY | 14.91% |
| 2018 | 12.37 Billion CNY | 46.14% |
| 2017 | 8.46 Billion CNY | 1.58% |
| 2016 | 8.33 Billion CNY | 17.71% |
| 2015 | 7.08 Billion CNY | 23.38% |
| 2014 | 5.73 Billion CNY | 24.26% |
| 2013 | 4.61 Billion CNY | 16.37% |
| 2012 | 3.96 Billion CNY | 38.98% |
| 2011 | 2.85 Billion CNY | 51.85% |
| 2010 | 1.88 Billion CNY | 18.48% |
| 2009 | 1.58 Billion CNY | 50.27% |
| 2008 | 1.05 Billion CNY | 75.78% |
| 2007 | 600.86 Million CNY | 67.37% |
| 2006 | 359 Million CNY | -25.62% |
| 2005 | 482.68 Million CNY | -25.56% |
| 2004 | 648.39 Million CNY | 22.89% |
| 2003 | 527.62 Million CNY | 21.17% |
| 2002 | 435.45 Million CNY | 28.66% |
| 2001 | 338.44 Million CNY | 43.94% |
| 2000 | 235.13 Million CNY | 39.37% |
| 1999 | 168.71 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 1.3 Billion USD | 0.0% |
| 2023 Q1 | 4.4 Billion USD | 293.44% |
| 2023 FY | 15.91 Billion CNY | -6.09% |
| 2023 Q3 | - USD | -100.0% |
| 2023 Q4 | 920.19 Million USD | 0.0% |
| 2023 Q2 | 1.26 Billion USD | -71.21% |
| 2022 Q4 | 1.11 Billion USD | -74.45% |
| 2022 Q1 | 4.26 Billion CNY | 240.04% |
| 2022 Q2 | 4.26 Billion CNY | 0.0% |
| 2022 FY | 16.94 Billion CNY | -1.38% |
| 2022 Q3 | 4.37 Billion USD | 2.74% |
| 2021 Q2 | 2.08 Billion CNY | -54.31% |
| 2021 Q4 | 1.25 Billion CNY | 0.0% |
| 2021 Q3 | 1.25 Billion CNY | -39.94% |
| 2021 FY | 17.18 Billion CNY | 21.36% |
| 2021 Q1 | 4.56 Billion CNY | 24.86% |
| 2020 Q3 | 3.08 Billion CNY | -11.44% |
| 2020 FY | 14.16 Billion CNY | -0.39% |
| 2020 Q1 | 3.93 Billion CNY | 38.15% |
| 2020 Q2 | 3.48 Billion CNY | -11.4% |
| 2020 Q4 | 3.65 Billion CNY | 18.55% |
| 2019 Q1 | 3.86 Billion CNY | 6.28% |
| 2019 FY | 14.21 Billion CNY | 14.91% |
| 2019 Q4 | 2.84 Billion CNY | -24.26% |
| 2019 Q3 | 3.75 Billion CNY | 0.2% |
| 2019 Q2 | 3.75 Billion CNY | -2.83% |
| 2018 FY | 12.37 Billion CNY | 46.14% |
| 2018 Q1 | 2.83 Billion CNY | 53.19% |
| 2018 Q2 | 2.97 Billion CNY | 4.92% |
| 2018 Q3 | 2.93 Billion CNY | -1.07% |
| 2018 Q4 | 3.63 Billion CNY | 23.59% |
| 2017 Q4 | 1.84 Billion CNY | -9.31% |
| 2017 Q3 | 2.03 Billion CNY | -5.09% |
| 2017 Q2 | 2.14 Billion CNY | -11.74% |
| 2017 Q1 | 2.43 Billion CNY | 18.86% |
| 2017 FY | 8.46 Billion CNY | 1.58% |
| 2016 Q3 | 1.99 Billion CNY | -1.85% |
| 2016 Q1 | 2.26 Billion CNY | 47.46% |
| 2016 Q4 | 2.04 Billion CNY | 2.77% |
| 2016 FY | 8.33 Billion CNY | 17.71% |
| 2016 Q2 | 2.02 Billion CNY | -10.49% |
| 2015 Q2 | 1.8 Billion CNY | -6.63% |
| 2015 FY | 7.08 Billion CNY | 23.38% |
| 2015 Q1 | 1.93 Billion CNY | 38.24% |
| 2015 Q4 | 1.53 Billion CNY | -14.34% |
| 2015 Q3 | 1.79 Billion CNY | -0.84% |
| 2014 Q4 | 1.4 Billion CNY | 4.42% |
| 2014 Q2 | 1.48 Billion CNY | -0.97% |
| 2014 Q1 | 1.5 Billion CNY | 50.42% |
| 2014 FY | 5.73 Billion CNY | 24.26% |
| 2014 Q3 | 1.34 Billion CNY | -9.85% |
| 2013 Q1 | 1.21 Billion CNY | 18.95% |
| 2013 Q2 | 1.24 Billion CNY | 3.02% |
| 2013 Q3 | 1.15 Billion CNY | -7.32% |
| 2013 Q4 | 999.97 Million CNY | -13.6% |
| 2013 FY | 4.61 Billion CNY | 16.37% |
| 2012 Q1 | 944.09 Million CNY | 41.69% |
| 2012 Q4 | 1.01 Billion CNY | -17.83% |
| 2012 Q3 | 1.24 Billion CNY | 62.07% |
| 2012 Q2 | 765.23 Million CNY | -18.95% |
| 2012 FY | 3.96 Billion CNY | 38.98% |
| 2011 Q2 | 728.79 Million CNY | 18.4% |
| 2011 Q1 | 615.54 Million CNY | 0.0% |
| 2011 FY | 2.85 Billion CNY | 51.85% |
| 2011 Q3 | 844.87 Million CNY | 15.93% |
| 2011 Q4 | 666.29 Million CNY | -21.14% |
| 2010 Q2 | 535.75 Million CNY | 17.58% |
| 2010 Q1 | 455.63 Million CNY | 0.0% |
| 2010 FY | 1.88 Billion CNY | 18.48% |
| 2009 FY | 1.58 Billion CNY | 50.27% |
| 2008 FY | 1.05 Billion CNY | 75.78% |
| 2007 FY | 600.86 Million CNY | 67.37% |
| 2006 FY | 359 Million CNY | -25.62% |
| 2005 FY | 482.68 Million CNY | -25.56% |
| 2004 FY | 648.39 Million CNY | 22.89% |
| 2003 FY | 527.62 Million CNY | 21.17% |
| 2002 FY | 435.45 Million CNY | 28.66% |
| 2001 FY | 338.44 Million CNY | 43.94% |
| 2000 FY | 235.13 Million CNY | 39.37% |
| 1999 FY | 168.71 Million CNY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | -17805.92% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -315880.641% |
| SQZ Biotechnologies Company | 85.61 Million USD | -18049.772% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -52482.32% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | -41610.838% |
| Mesoblast Limited | 5.9 Million USD | -263194.697% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -1034566.978% |
| Genus plc | 147.7 Million USD | -10421.092% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -176904.657% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -1158240.048% |
| Marizyme, Inc. | 19.23 Million USD | -80668.132% |
| ContraFect Corporation | 56.88 Million USD | -27215.743% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -186249.119% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -352379.227% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -1050762.687% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -532766.967% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -556805.55% |
| MultiCell Technologies, Inc. | 567.42 USD | -2738650811.142% |
| Accustem Sciences Inc. | 3.74 Million USD | -414686.84% |
| RVL Pharmaceuticals plc | 85.94 Million USD | -17980.927% |
| EV Biologics, Inc. | 531.96 Thousand USD | -2921096.063% |
| Q BioMed Inc. | 3.43 Million USD | -452077.338% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -62775.391% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -3988865.413% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -591318.569% |
| Biomind Labs Inc. | 994.18 Thousand USD | -1562959.178% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 225.49 Million USD | -6791.474% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -231213.163% |
| Skye Bioscience, Inc. | 13.54 Million USD | -114604.526% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -758411.011% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 62158712.0% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -308101.456% |
| IMV Inc. | 37.7 Million USD | -41109.166% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -96960.731% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -846703.735% |
| GB Sciences, Inc. | 1.42 Million USD | -1093849.634% |
| Alpha Cognition Inc. | 9.7 Million USD | -160010.157% |
| HST Global, Inc. | 140.9 Thousand USD | -11028204.485% |
| CSL Limited | 3.44 Billion USD | -350.555% |
| Halberd Corporation | 74.84 Thousand USD | -20763178.64% |
| Enzolytics Inc. | 2.17 Million USD | -712889.36% |
| Resverlogix Corp. | 12.71 Million USD | -122143.966% |
| Affymax, Inc. | 39.38 Million USD | -39354.763% |
| SYBLEU INC | 160.87 Thousand USD | -9659297.921% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -425561.468% |
| argenx SE | 1.53 Billion USD | -913.326% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | -26953.713% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -1488372.51% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -983824.007% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -456280.289% |
| AVAX Technologies, Inc. | 7.31 Million USD | -212473.075% |
| Zenith Capital Corp. | 8.94 Million USD | -173663.312% |
| Genscript Biotech Corporation | 825.34 Million USD | -1782.809% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -89200594.564% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -632798.033% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -9060446.677% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | -15544.444% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -882996.396% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 1.97 Million USD | -787901.272% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -833406.922% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -142898.555% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -808875.192% |
| BioStem Technologies, Inc. | 22.97 Million USD | -67537.81% |
| ONE Bio Corp. | 6.44 Million USD | -241053.219% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -8562399.931% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -1163543.273% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -1381313.002% |
| Agentix Corp. | 1.37 Million USD | -1132729.235% |
| LadRx Corporation | 3.81 Million USD | -407573.27% |
| Cell Source, Inc. | 4.32 Million USD | -359169.594% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -3740077.723% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -1682572.954% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -1682572.954% |
| NovAccess Global Inc. | 2.46 Million USD | -629861.841% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -646057.15% |
| Itoco Inc. | 919.14 Thousand USD | -1690567.611% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -366538.394% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -1388608.937% |
| Kadimastem Ltd | 2.41 Million USD | -644668.915% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -5937274.583% |
| CytoDyn Inc. | 18.05 Million USD | -85954.12% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -61741141.209% |
| Mobile Lads Corp. | 554.54 Thousand USD | -2802129.752% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -7060875.2% |
| Qrons Inc. | 643.67 Thousand USD | -2414100.445% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -1094402.082% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -696783.239% |
| Rebus Holdings, Inc. | 664 Thousand USD | -2340209.187% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -855457.005% |
| International Stem Cell Corporation | 5.27 Million USD | -294714.134% |
| Bioxytran, Inc. | 3.82 Million USD | -406681.545% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -29519395.84% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -76388107.246% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | -42749.096% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -960323.548% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -2111739.339% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -499406.686% |
| Neutra Corp. | 243.82 Thousand USD | -6373285.804% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -88916.744% |
| PureTech Health plc | 144.59 Million USD | -10646.871% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -75740.595% |
| IXICO plc | 4.7 Million USD | -330039.218% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -176547.187% |
| Gelesis Holdings, Inc. | 117.74 Million USD | -13097.382% |
| CSL Limited | 3.89 Billion USD | -299.169% |
| Cellectis S.A. | 97.32 Million USD | -15867.584% |